Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma
Phase 2
- Conditions
- Peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma
- Registration Number
- JPRN-UMIN000010485
- Lead Sponsor
- Yokohama City University Hopsital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria were the presence of serious infection; active tuberculosis; diabetes mellitus uncontrollable with insulin, liver cirrhosis, arrhythmia, or other abnormal electrocardiographic finding requiring treatment, concomitant malignant disease other than basal cell carcinoma of the skin or carcinoma in situ of the uteric cervix; central nervous system (CNS) lymphoma; pregnancy or breast feeding; mental disorders; and positivity for hepatitis B surface antigen, human T-lymphotrophic virus-1 antibody, or human immunodeficiency virus antibody. Patients were also excluded if the treating physician considered the protocol too difficult for the patients to carry out.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate and safety
- Secondary Outcome Measures
Name Time Method progression-free survival and overall survival